Toshinao Kawai1, Katsuhiro Arai2, Shizuko Harayama3, Yumiko Nakazawa4, Fumihiro Goto4, Takanobu Maekawa5, Eiichiro Tamura3, Toru Uchiyama4, Masafumi Onodera4. 1. Department of Human Genetics, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. kawai-t@ncchd.go.jp. 2. Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan. 3. Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan. 4. Department of Human Genetics, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. 5. Department of Pediatrics, National Center for Child Health and Development, Tokyo, Japan.
Abstract
PURPOSE: Chronic granulomatous disease (CGD) is a primary immunodeficiency disease that leads to recurrent infection and hyper-inflammation, occasionally represented by CGD-associated colitis (CGD colitis). Although clinical symptoms of CGD colitis mimic those of ulcerative colitis (UC), there is no reliable standard measurement of disease activity or standard therapeutic strategy for CGD colitis. Here, we examined the clinical manifestation of CGD colitis based on severity using a noninvasive measure of disease activity, the Pediatric Ulcerative Colitis Activity Index (PUCAI), which has been validated and widely used for pediatric UC. METHODS: Sixteen of 35 CGD patients, who were diagnosed with CGD colitis based on colonoscopic and histological findings, were examined using the PUCAI. Both the PUCAI and the physician global assessment (PGA) tool were retrospectively scored by reviewing medical records. RESULTS: Disease activity defined by PUCAI was correlated with PGA, and increased at diagnosis of CGD colitis, especially in patients who were younger than 6 years of age (very early-onset CGD colitis: VEO-CGD colitis) when diagnosed with CGD colitis. All severe patients had a more progressive form of VEO-CGD colitis. Unlike mild and moderate patients, severe patients required multidrug therapy of corticosteroids and immunomodulator/immunosuppressants, and some were eventually treated with hematopoietic stem cell transplantation. CONCLUSIONS: Although the validation of PUCAI in CGD colitis should be considered for future use, our results indicate that noninvasive measures could be effective to measure disease activity and help to determine suitable treatment for CGD colitis. In patients with VEO-CGD colitis, multidrug therapy would need to be considered at an early stage on the basis of disease activity.
PURPOSE:Chronic granulomatous disease (CGD) is a primary immunodeficiency disease that leads to recurrent infection and hyper-inflammation, occasionally represented by CGD-associated colitis (CGD colitis). Although clinical symptoms of CGD colitis mimic those of ulcerative colitis (UC), there is no reliable standard measurement of disease activity or standard therapeutic strategy for CGD colitis. Here, we examined the clinical manifestation of CGD colitis based on severity using a noninvasive measure of disease activity, the Pediatric Ulcerative Colitis Activity Index (PUCAI), which has been validated and widely used for pediatric UC. METHODS: Sixteen of 35 CGDpatients, who were diagnosed with CGD colitis based on colonoscopic and histological findings, were examined using the PUCAI. Both the PUCAI and the physician global assessment (PGA) tool were retrospectively scored by reviewing medical records. RESULTS: Disease activity defined by PUCAI was correlated with PGA, and increased at diagnosis of CGD colitis, especially in patients who were younger than 6 years of age (very early-onset CGD colitis: VEO-CGD colitis) when diagnosed with CGD colitis. All severe patients had a more progressive form of VEO-CGD colitis. Unlike mild and moderate patients, severe patients required multidrug therapy of corticosteroids and immunomodulator/immunosuppressants, and some were eventually treated with hematopoietic stem cell transplantation. CONCLUSIONS: Although the validation of PUCAI in CGD colitis should be considered for future use, our results indicate that noninvasive measures could be effective to measure disease activity and help to determine suitable treatment for CGD colitis. In patients with VEO-CGD colitis, multidrug therapy would need to be considered at an early stage on the basis of disease activity.
Authors: Meghna Alimchandani; Jin-Ping Lai; Phyu Phyu Aung; Sajneet Khangura; Natasha Kamal; John I Gallin; Steven M Holland; Harry L Malech; Theo Heller; Markku Miettinen; Martha M Quezado Journal: Am J Surg Pathol Date: 2013-09 Impact factor: 6.394
Authors: Douglas B Kuhns; W Gregory Alvord; Theo Heller; Jordan J Feld; Kristen M Pike; Beatriz E Marciano; Gulbu Uzel; Suk See DeRavin; Debra A Long Priel; Benjamin P Soule; Kol A Zarember; Harry L Malech; Steven M Holland; John I Gallin Journal: N Engl J Med Date: 2010-12-30 Impact factor: 91.245
Authors: Baldassarre Martire; Roberto Rondelli; Annarosa Soresina; Claudio Pignata; Teresa Broccoletti; Andrea Finocchi; Paolo Rossi; Marco Gattorno; Marco Rabusin; Chiara Azzari; Rosa M Dellepiane; Maria C Pietrogrande; Antonino Trizzino; Paolo Di Bartolomeo; Silvana Martino; Luigi Carpino; Fausto Cossu; Franco Locatelli; Rita Maccario; Paolo Pierani; Maria C Putti; Achille Stabile; Luigi D Notarangelo; Alberto G Ugazio; Alessandro Plebani; Domenico De Mattia Journal: Clin Immunol Date: 2007-11-26 Impact factor: 3.969
Authors: Beatriz E Marciano; Sergio D Rosenzweig; David E Kleiner; Victoria L Anderson; Dirk N Darnell; Sandra Anaya-O'Brien; Dianne M Hilligoss; Harry L Malech; John I Gallin; Steven M Holland Journal: Pediatrics Date: 2004-08 Impact factor: 7.124
Authors: Dan Turner; Anthony R Otley; David Mack; Jeffrey Hyams; J de Bruijne; Krista Uusoue; Thomas D Walters; Mary Zachos; Petar Mamula; Dorcas E Beaton; A Hillary Steinhart; Anne M Griffiths Journal: Gastroenterology Date: 2007-05-21 Impact factor: 22.682